Summit Therapeutics plc — 2019 Transition Report Summary
Business context and reporting period
This is Summit Therapeutics plc’s transition report for the 11 months ended December 31, 2019, following a change in fiscal year-end from January 31 to December 31. Financial statements are prepared under IFRS in pounds sterling; U.S. dollar figures are convenience translations. Summit is a clinical-stage biopharmaceutical company focused on antibiotics. Its U.S. subsidiary is Summit Therapeutics Inc.
The lead program, ridinilazole, is being developed for Clostridioides difficile infection (CDI) in two Phase 3 trials. Other antibiotic programs, including candidates for Enterobacteriaceae and gonorrhea, remained early-stage. The company had no marketed drugs.
Key financial metrics
| Metric | 11 months ended Dec. 31, 2019 | Balance at Dec. 31, 2019 |
|---|---|---|
| Revenue | £0.583 million | |
| Other operating income, primarily grant funding | £15.163 million | |
| Research and development expense | £31.201 million | |
| General and administrative expense | £9.877 million | |
| Operating loss | £25.332 million | |
| Net loss | £22.032 million | |
| Basic and diluted loss per share | £0.13 | |
| Cash and cash equivalents | £48.417 million | |
| Working capital | £2.181 million | |
| Total assets / total liabilities | £73.123 million / £13.898 million | |
| Total equity | £59.225 million |
Cash flows were £15.667 million used in operations, £0.263 million used in investing activities and £37.701 million provided by financing activities. Cash increased by £21.771 million during the period. The company reported no conventional borrowings; lease liabilities totaled £0.678 million.
Material changes versus prior periods
- The £7.490 million profit reported for the year ended January 31, 2019, was driven by recognition of remaining deferred Sarepta collaboration revenue after Summit discontinued ezutromid development. The recognition did not generate cash. Sarepta revenue recognized in that prior year was £42.3 million; the agreement terminated in August 2019.
- Revenue fell to £0.583 million in the transition period. Comparisons with the prior January year are not like-for-like because the current period covers 11 months while the prior period covers 12 months.
- R&D spending was £31.201 million, with increased investment in CDI and antibiotic pipeline work offset by lower DMD spending following ezutromid’s discontinuation. The prior year included a £3.985 million impairment of DMD-related goodwill and intangible assets.
- A December 2019 share placement generated net proceeds of approximately £38.1 million (about $49.1 million). Ordinary shares outstanding rose to 335,890,281 at period-end; the placement also included warrants.
Outlook, risks and unusual items
- Management estimated existing cash plus anticipated BARDA, CARB-X and Eurofarma receipts would fund operating and capital requirements to January 31, 2021. Summit stated it would need additional capital beyond then and did not expect to complete the two Phase 3 trials without additional funding. The audited financial statements identify a material uncertainty that may cast significant doubt on the company’s ability to continue as a going concern.
- BARDA’s contract could provide up to $72.5 million, with $62.4 million committed following an added option in January 2020; $38.6 million had been received as of December 31, 2019. Further funding depended on BARDA exercising its remaining option. CARB-X support was also partly conditional on options and milestones.
- COVID-19 had slowed or suspended enrollment at some Phase 3 sites. Summit withdrew its expected trial-completion timing and anticipated delayed results; possible clinical supply replacement and further operational disruption were also identified. COVID-19 was treated as a non-adjusting post-balance-sheet event.
- Ridinilazole’s Phase 3 program compares the drug with vancomycin on sustained clinical response. Earlier Phase 2 results favored ridinilazole, but those results do not establish Phase 3 success. Manufacturing issues with tablet-form clinical supply had previously delayed trial commencement until February 2019.
- Key risks include clinical failure or delay, dependence on ridinilazole, need for further financing and potential dilution, reliance on third-party manufacturers and funders, reimbursement and generic competition, and intellectual-property limitations. The filing notes that ridinilazole lacks active-ingredient composition-of-matter patent protection.
- Related-party matters include a consulting agreement with Maky Zanganeh & Associates at $75,000 per month and warrants for 16,793,660 shares; the firm’s leadership included a major shareholder and a company director. Robert W. Duggan’s December placement and associated warrants gave him substantial control; the filing reports beneficial ownership of approximately 62.8% as of April 1, 2020.
- The auditor issued an unqualified opinion on the IFRS financial statements and emphasized the need for additional financing. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not attest to internal-control effectiveness.
Most important facts for investors to verify
- Current cash runway, financing plans and any subsequent funding, given the stated January 2021 runway estimate and going-concern uncertainty.
- Updated enrollment, site status, timelines and results for both Ri-CoDIFy Phase 3 trials, including the impact of COVID-19.
- BARDA’s remaining option decisions and receipts, CARB-X milestone funding, and Eurofarma milestone payments and obligations.
- Whether ridinilazole’s manufacturing and supply chain can support trials and potential commercial production, and the implications of its patent scope.
- Potential dilution from outstanding warrants and options, ownership concentration, and the terms and governance of the related-party consulting arrangement.